Yunding Xinyao applied for listing on the Hong Kong Stock Exchange to accelerate the development of eight new drugs.

On July 20th Everest Products, a co-sponsor of Goldman Sachs and Bank of America, filed for listing with the Hong Kong Stock Exchange.
Previously, on June 5, Yumding Xinyao announced the completion of a $310 million round of C financing, which will be used to advance the clinical development of Yunding Xinyao's innovative pharmaceutical product pipeline and build a strong commercial infrastructure for the next phase of growth. founded in 2017,
Yunding Xinyao is a biopharmaceutical company focused on innovative drug development and commercialization, dedicated to meeting the unsealed medical needs of China (including the Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan) and other Asian markets, with a pipeline covering four areas: tumors, immunological diseases, infectious diseases, and heart and kidney diseases.
has so far established eight potentially world-first or best-in-class molecular combinations, many of which are in the late stages of clinical development.
the Hong Kong listing will be used for clinical trials and subsequent commercialization of four major products: Sacituzumab govitecan (BLA submitted by China by the end of 2021 or in the first half of 2022), Xerava (Eravacycline, China submitted NDA in the first half of 2021), Etrasimod, Nefecon (China submitted NDA in 2022), and other early clinical trials.
Sacituzumab govitecan, a class-first anti-Trap-2 antibody drug coupled (ADC), has been approved in the United States for the treatment of metastasis triple negative breast cancer (TNBC) patients who have received at least two treatments in the past.
The most difficult type of breast cancer is TNBC, tri-negative refers to estrogen, progesterone-like and human epithetogen growth factor 2 (HER2) are negative, 10% to 20% of breast cancer patients with triple-negative breast cancer, for these patients, their treatment options are limited; It is a membrane antigen that is overexpressed in many common epithelial cancers, so sacituzumab govitecan may have a broad-spectrum anti-tumor effect;
Xerava (Eravacycline) is a new, fully synthesized broad-spectrum tetrahedrin non-intestinal antibiotic that has a wide range of in-body antibacterial activity against drug-resistant bacteria commonly found in China, such as multi-drug resistant Terranean-negative bacteria.
is currently approved in the United States and Europe for the treatment of complex intracaropathic infection (cIAI) patients, and iracycline was approved by Singapore in April 2020.
Yumding Xinyao is currently conducting Phase III clinical trials of the allergy in China to support regulatory approval.
Etrasimod is a potentially best-in-class oral regulator for second-generation 1-phosphate pyrethroid (S1P) subjects.
Yunding Xinyao is conducting multi-center Phase III clinical trials of ulcerative colitis (UC) in China and South Korea.
Nefecon is a potentially world-first innovative product for IgA nephropathy (IgAN), an oral targeted release agent for Budinide.
December 2019, Yunding Xinyao obtained clinical trial application (IND) approval for IgA kidney disease.
will conduct a global Phase III clinical trial with its partner, Caleditas Therapeutics.
We look forward to Yunding New Yaogang Stock Exchange listing application to obtain registration approval, I hope that the company can be successfully listed, with the help of capital, will be more research products to the market! Reference: The clinical late-stage pharmaceutical company Yunding Xinyao applied for listing on the Hong Kong Stock Exchange to introduce 8 classes of drugs into China. Retrieved 2020-07-20, from.